Tyler Martin, M.D.

Tyler Martin, M.D.

CEO, Adjuvance Technologies

Dr. Martin is the Chairman and CEO of Adjuvance Technologies, a vaccine adjuvant company, with headquarters in Lincoln, NE, based on intellectual property from Memorial Sloan Kettering Cancer Center in New York, NY. Prior to Adjuvance, he held senior leadership positions in a number of biotech companies including Chiron, Sangamo, and Dynavax. He has led teams that filed more than 100 Investigational New Drug (IND) Applications including two adjuvanted vaccines approved by major regulatory authorities, Fluad and Heplisav-B.

Dr. Martin received a bachelor’s degree with honors from the University of Nebraska at Kearney, and an MD degree from the University of Nebraska College of Medicine. He was a resident in Pediatrics at the University of Nebraska Medical Center and was a post-doctoral fellow in Molecular Microbiology and Pediatric Infectious Diseases at Washington University in St. Louis.